AUPH - （Aurinia Pharmaceuticals Inc）

Aurinia Pharmaceuticals Inc. announced promising results from … eGFR-based dosing protocol. Aurinia Pharmaceuticals is a fully integrated biopharmaceutical …

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) shares are trading higher Wednesday after the company announced "promising results" from its AURORA Renal Biopsy Sub-Study . The Details: The study showed that the addition of the company''s oral medicine for the treatment of adult patients with active lupus nephritis, LUPKYNIS, on top of the current standard of care resulted in significantly earlier and greater reductions in proteinuria while maintaining … Full story available on Benzinga.com

Aurinia Pharmaceuticals (AUPH) said biopsy data collected from AURORA program showed promising data for Lupkynis to treat lupus nephritis. Read more here

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced promising results from the AURORA Renal Biopsy Sub-Study. LUPKYNIS is a novel agent approved for the treatment of adults with active lupus nephritis (LN). The addition of LUPKYNIS on top of the then current standard of care MMF and low-dose steroids in Aurinia’s Phase 3 AURORA 1 and AURORA 2 studies led to significantly earlier and greater reductions in proteinuria while main

My original investment thesis on Aurinia Pharma was that without a buyout, it has no future. Is that still the case? Click here for a full analysis of AUPH stock.

The following slide deck was published by Aurinia Pharmaceuticals Inc.

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Morning Stocks in Queue: Hycroft Mining Holding Corporation (NASDAQ:HYMC -5.61%), Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH 1.47%) appeared first on Stocks Equity .

Aurinia Pharmaceuticals (NASDAQ: AUPH ) brought in sales totaling $28.43 million during Q4 according to data provided by Benzinga Pro . However, earnings decreased 189.75%, resulting in a loss of $26.05 million. In Q3, Aurinia Pharmaceuticals brought in $55.78 million in sales but lost $8.99 million in earnings. What Is ROCE? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company … Full story available on Benzinga.com

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), Cinemark Holdings, Inc. (NYSE:CNK) – Shocking stocks appeared first on Stocks Equity .

Aurinia Pharmaceuticals Inc. (NASDAQ:NASDAQ:AUPH) Q4 2022 Earnings Conference Call February 28, 2023 8:30 AM ETCompany ParticipantsDana Lynch - Director of Corporate Communications &…

Currently, Aurinia Pharmaceuticals Inc.’s (AUPH) stock is trading at $4.35, marking a gain of 4.82% from last night’s close. At this price, the stock is -81.87% below its 52-week high of $24.00 and 6.88% above its 52-week low of $4.07. Based on the past 30-day period, the stock price is -16.51% below the high and […]

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) shares, rose in value on Wednesday, 12/28/22, with the stock price up by 0.97% to the previous day’s close as strong demand from buyers drove the stock to $4.15. Actively observing the price movement in the last trading, the stock closed the session at $4.11, falling within a range of $4.07 … Is Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) A Suitable Stock For New Investors Today? Read More »

In the last trading session, 2.32 million shares of the Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) were traded, and its beta was 0.85. Most recently the company’s share price was $4.11, and it changed around -$0.42 or -9.27% from the last close, which brings the market valuation of the company to $595.62M. AUPH currently trades at a … Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) Stock Forecast: By 2022, Bulls Expect $15.00 Per Share Read More »

A share of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) closed at $4.53 per share on Thursday, down from $4.67 day before. While Aurinia Pharmaceuticals Inc. has underperformed by -3.00%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AUPH fell by -77.20%, with highs and lows ranging from $24.45 […]

A share of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) closed at $4.65 per share on Wednesday, down from $4.78 day before. While Aurinia Pharmaceuticals Inc. has underperformed by -2.72%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AUPH fell by -76.99%, with highs and lows ranging from $24.45 […]